Impella® is a percutaneously inserted ventricular assist device. Its use increased from 11 devices placed in 2016 to 39 in 2019 at Valley Baptist Medical Center (VBMC). We review the anticoagulation options, side effects, and mortality.
Retrospective chart review of 107 patients placed on Impella from 2016-2020 admitted to VBMC. Descriptive statistics were used to assess the distribution of variables; continuous variables summarized as mean values with standard deviations and categorical variables as counts/percentages.
Indication for Impella was protected percutaneous coronary intervention (PCI) (71%, of which 18.4% was intervention on a previous coronary artery bypass graft, CABG), cardiogenic shock (17.7%), or coronary angiogram prior to CABG (11.3%). The average duration of being placed on support was 1.3±1.8 days.
Periprocedural anticoagulants administered by cardiologists were heparin (H), bivalirudin (B), or both. Some received enoxaparin (E) [dosed as per ACS protocol] for ≥24hrs before the procedure. Anticoagulation groups are H (55.1%), B (22.4%), H+B (7.5%), E+H (3.7%), E+B (8.4%), and none (2.8%). Observed side effects were acute bleeding (18.7%) with hemoglobin ≤7 mg/dl by group is 10.1% vs 20.8% vs 37.5% vs 50% vs 33.3 respectively (p=0.06), femoral pseudoaneurysm (2.8%) and retroperitoneal bleed (0.9%). Average aPTT was 70-140 seconds in the heparin group, ACT (measured in 9.3%) of 275±212.4, fibrinogen (in 12.1%) of 356±125.8.
Death within a month (32/107) occurred when the indication was cardiogenic shock (83.3%) versus protected PCI (28.9%) (p=0.00018).
In agreeance with the manufacturer's recommendation, the lowest risk of bleeding is observed with heparin (dosing: weight-based) only. Further clinical studies required for having a standardized protocol with dosing and duration of therapy.
Thunuguntla, Supraja and Mild, Charles F., "Single Center Study of the Impella Pump" (2020). School of Medicine Publications and Presentations. 84.